Analyst Ratings for ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) received 7 analyst ratings in the last quarter, with 3 bullish, 3 somewhat bullish, and 1 indifferent. No somewhat bearish or bearish ratings were given. The average 12-month price target for ACAD is $33.00, with a high of $42.00 and a low of $25.00. This target has increased by 10% over the past month. Analysts rate stocks to guide investors, and these ratings are updated quarterly.
December 12, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals has a favorable analyst outlook with 6 out of 7 ratings being positive and an average price target that has increased by 10% over the past month.
The positive analyst ratings and the increase in the average price target suggest a bullish sentiment towards ACADIA Pharmaceuticals. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100